Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.

  title={Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.},
  author={Edward T. H. Yeh and A. S. T. Tong and Daniel J. Lenihan and Syed Wamique Yusuf and Joseph Swafford and Christopher Champion and J D Durand and Harry Gibbs and Alireza Atef Zafarmand and Michael S. Ewer},
  volume={109 25},
The cardiotoxicity of anticancer agents can lead to significant complications that can affect patients being treated for various malignancies. The severity of such toxicity depends on many factors such as the molecular site of action, the immediate and cumulative dose, the method of administration, the presence of any underlying cardiac condition, and the demographics of the patient. Moreover, toxicity can be affected by current or previous treatment with other antineoplastic agents… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 250 extracted citations

Cardiovascular effects of systemic cancer treatment.

Cancer treatment reviews • 2011
View 10 Excerpts
Highly Influenced

Thoracic emergencies in immunocompromised patients.

Emergency medicine clinics of North America • 2012
View 4 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 106 references

B-type natriuretic peptide is a biochemical predictor of myocardial contractile reserve during dobutamine stress echocardiogram

AT Tong, D Lenihan, V Divakaran
J Am Coll Cardiol • 2004

Clinical cardiac tolerability of trastuzumab.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2004

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor

LB Saltz, NJ Meropol, PJ SrLoehrer
J Clin Oncol • 2004

Withdrawal of ACE-inhibitors and beta-blockers in chemotherapy induced heart failure leads to severe adverse cardiovascular events. Circulation

DJ Lenihan, AT Tong, M Woods

Similar Papers

Loading similar papers…